{"id":"experimental-tezepelumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TSLP is produced by epithelial cells and activates dendritic cells and innate lymphoid cells to promote type 2 immune responses. By neutralizing TSLP, tezepelumab reduces downstream production of type 2 cytokines (IL-4, IL-5, IL-13) and suppresses eosinophilic and allergic inflammation. This upstream mechanism of action addresses a fundamental driver of asthma across multiple phenotypes.","oneSentence":"Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key upstream cytokine involved in type 2 inflammation and asthma pathogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:38.018Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe asthma (including eosinophilic and allergic phenotypes)"},{"name":"Severe asthma with oral corticosteroid dependence"}]},"trialDetails":[{"nctId":"NCT04851964","phase":"PHASE3","title":"Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-04-22","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":416},{"nctId":"NCT05280418","phase":"PHASE3","title":"Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma","status":"COMPLETED","sponsor":"McMaster University","startDate":"2022-11-08","conditions":"Asthma","enrollment":27},{"nctId":"NCT03927157","phase":"PHASE3","title":"Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-06-14","conditions":"Asthma","enrollment":405},{"nctId":"NCT06230354","phase":"PHASE2","title":"Explore the Efficacy and Mechanism of Action of Tezepelumab in Eosinophilic Granulomatosis With Polyangiitis","status":"ENROLLING_BY_INVITATION","sponsor":"Imperial College London","startDate":"2024-05","conditions":"EGPA - Eosinophilic Granulomatosis With Polyangiitis","enrollment":66},{"nctId":"NCT04048343","phase":"PHASE3","title":"Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-06-10","conditions":"Severe Asthma","enrollment":65},{"nctId":"NCT03347279","phase":"PHASE3","title":"Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-11-23","conditions":"Asthma","enrollment":1061},{"nctId":"NCT04362410","phase":"PHASE1","title":"Tezepelumab Phase 1 PK Study in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-05-18","conditions":"Healthy Subjects","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":58,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tezepelumab"],"phase":"phase_3","status":"active","brandName":"Experimental: Tezepelumab","genericName":"Experimental: Tezepelumab","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Biologic","firstApprovalDate":"","aiSummary":"Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP), a key upstream cytokine involved in type 2 inflammation and asthma pathogenesis. Used for Moderate-to-severe asthma (including eosinophilic and allergic phenotypes), Severe asthma with oral corticosteroid dependence.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":7,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}